About PharmEcon Consulting
PharmEcon Consulting is a specialized healthcare advisory firm focused on market access, health economics and outcomes research (HEOR), real-world evidence (RWE), health technology assessment (HTA), reimbursement strategy, and public policy.
We partner with pharmaceutical, biotechnology, medical technology, and healthcare organizations to generate evidence, articulate value, and navigate complex reimbursement and policy environments. Our approach combines scientific rigor, strategic insight, and deep healthcare system expertise to support informed decision-making and accelerate patient access to innovation.
Services
Strategic, evidence-based support across the product lifecycle — from early evidence planning to reimbursement, launch, and post-market value demonstration.
Market Access Strategy
End-to-end access planning, reimbursement pathway assessment, payer engagement strategy, value proposition development, and launch readiness support.
HTA & Reimbursement
Support for CDA-AMC, INESSS, provincial payer, and private payer strategy, including evidence gap assessment, submission planning, and payer-ready narratives.
Health Economics & HEOR
Economic evaluation strategy, budget impact planning, cost-effectiveness model interpretation, burden-of-disease evidence, and value communication.
Real-World Evidence
RWE strategy, integrated evidence generation planning, database study concepts, treatment pathway mapping, outcomes research, and evidence translation.
Evidence Generation Planning
Identification of evidence gaps, cross-functional evidence planning, study prioritization, vendor oversight, and development of payer-relevant evidence packages.
Public Policy & Stakeholder Engagement
Policy landscape assessment, stakeholder mapping, patient and system value narratives, and strategic engagement with healthcare decision-makers.
Core Expertise
Evidence to Value
Translating clinical, economic, and real-world evidence into compelling value narratives for payers, policymakers, clinicians, and healthcare stakeholders.
Canadian Access Landscape
Deep knowledge of Canadian HTA, public and private payer environments, provincial decision-making, reimbursement pathways, and health system priorities.
Cross-Functional Leadership
Collaboration across Medical Affairs, HEOR, Regulatory, Commercial, Government Affairs, Global teams, external vendors, and stakeholder groups.
Bahareh Vali, PhD
Founder & Principal Consultant
Market Access, HEOR, Real-World Evidence, and HTA leader with experience across pharmaceutical, biotechnology, medical technology, consulting, and healthcare decision-making environments.
Strategic expertise: Extensive experience in reimbursement strategy, evidence generation, payer engagement, and health policy across Canada and global markets.
Industry leadership: Experience developing access strategies, evidence generation plans, HTA submissions, payer value propositions, and reimbursement approaches across oncology, medical technology, vaccines, and specialty healthcare.
Health system perspective: Background in health technology assessment, evidence synthesis, economic evaluation, stakeholder consultation, and decision-support processes within the Canadian healthcare environment.
Consulting approach: Practical, evidence-driven, and commercially aware — helping organizations connect data, value, and policy to support better access decisions.
Partner With Us
We help healthcare organizations transform evidence into value and accelerate access to innovation.
Email: Info@pharmeconconsulting.ca
Email PharmEcon Consulting View Services